| Property | Value |
|---|
|
?:abstract
|
-
The end of 2019 saw the beginning of the COVID-19 pandemic that soared in 2020, affecting 215 countries worldwide with no signs of abating. In an effort to contain the spread of the disease and treat the infected, researchers are racing against several odds to find an effective solution. The unavailability of timely and affordable or definitive treatment has caused significant morbidity and mortality. Acute respiratory distress syndrome (ARDS) caused by an unregulated host inflammatory response towards the viral infection, followed by multi-organ dysfunction or failure, is one of the primary causes of deaths in severe cases of COVID-19 infection. Currently, empirical management of respiratory and hematological manifestations along with anti-viral agents are being used to treat the infection. The quest is on for both a vaccine and more a definitive management protocol to curtail the spread. Researchers and clinicians are also exploring the possibility of using cell therapy for severe cases of COVID-19 with ARDS. Mesenchymal stem cells are known to have immunomodulatory properties and have previously been used to treat viral infections. This review explores the potential of mesenchymal stem cells as cell therapy for ARDS.
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:doi
|
-
10.1016/j.jcyt.2020.11.001
|
|
?:doi
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/a6f8786eeb2167a718c3852c67904f0e82414eca.json
|
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7649634.xml.json
|
|
?:pmcid
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
Stem cell therapy in COVID-19 – current evidence and future potential
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}